BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28274247)

  • 1. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
    Xiong J; Li J; Yang Q; Wang J; Su T; Zhou S
    Breast Cancer Res; 2017 Mar; 19(1):27. PubMed ID: 28274247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
    Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
    Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions.
    Ma J; Xue Y; Cui W; Li Y; Zhao Q; Ye W; Zheng J; Cheng Y; Ma Y; Li S; Han T; Miao L; Yao L; Zhang J; Liu W
    Cancer; 2012 Sep; 118(17):4105-16. PubMed ID: 22907703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis.
    Pang X; Wu Y; Wu Y; Lu B; Chen J; Wang J; Yi Z; Qu W; Liu M
    Mol Cancer Ther; 2011 May; 10(5):795-805. PubMed ID: 21372225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
    Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
    Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells in vitro and in vivo.
    Niu X; Li S; Wei F; Huang J; Wu G; Xu L; Xu D; Wang S
    Breast Cancer; 2014 Mar; 21(2):223-30. PubMed ID: 22711315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
    Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
    Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
    Qin JJ; Wang W; Sarkar S; Voruganti S; Agarwal R; Zhang R
    Oncotarget; 2016 May; 7(22):32566-78. PubMed ID: 27105525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Oct; 6(32):33106-19. PubMed ID: 26461225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
    Pairawan S; Zhao M; Yuca E; Annis A; Evans K; Sutton D; Carvajal L; Ren JG; Santiago S; Guerlavais V; Akcakanat A; Tapia C; Yang F; Bose PSC; Zheng X; Dumbrava EI; Aivado M; Meric-Bernstam F
    Breast Cancer Res; 2021 Mar; 23(1):29. PubMed ID: 33663585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival.
    Liu T; Zhang H; Xiong J; Yi S; Gu L; Zhou M
    Mol Cancer; 2015 Mar; 14():65. PubMed ID: 25888903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.